Nature Communications

Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial

2026-01-08

Full text

DOI https://doi.org/10.1038/s41467-025-68108-2